Serum sulfatase activity is more elevated in colonic adenomas than cancers

Matusiewicz, Małgorzata; Krzystek−Korpacka, Małgorzata; Diakowska, Dorota; Grabowski, Krzysztof; Augoff, Katarzyna; Blachut, Katarzyna; Paradowski, Leszek; Kustrzeba−Wójcicka, Irena; Piast, Michał; Banaś, Teresa

doi:10.1007/s00384-007-0434-4

Cited by 6 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colon cancer biomarkers were also differentially expressed in these two groups of patients (Tables 1 and 2), namely EFEMP2 , a serum biomarker for early detection of colon cancer [65] and SULF1 , a protein important in colon cancer diagnosis [66] and whose serum level is elevated in patients with colon adenomas [67]. Genes that are implicated in angiogenesis were also identified (Tables 1 and 2); both VCAN [68], [69] and ANTXR1 [70], [71], [72] promote angiogenesis for cancer progression.…”

Section: Discussionmentioning

confidence: 99%

TAZ Expression as a Prognostic Indicator in Colorectal Cancer

et al. 2013

View full text Add to dashboard Cite

The Hippo pathway restricts the activity of transcriptional coactivators TAZ (WWTR1) and YAP. TAZ and YAP are reported to be overexpressed in various cancers, however, their prognostic significance in colorectal cancers remains unstudied. The expression levels of TAZ and YAP, and their downstream transcriptional targets, AXL and CTGF, were extracted from two independent colon cancer patient datasets available in the Gene Expression Omnibus database, totaling 522 patients. We found that mRNA expressions of both TAZ and YAP were positively correlated with those of AXL and CTGF (p<0.05). High level mRNA expression of TAZ, AXL or CTGF significantly correlated with shorter survival. Importantly, patients co-overexpressing all 3 genes had a significantly shorter survival time, and combinatorial expression of these 3 genes was an independent predictor for survival. The downstream target genes for TAZ-AXL-CTGF overexpression were identified by Java application MyStats. Interestingly, genes that are associated with colon cancer progression (ANTXR1, EFEMP2, SULF1, TAGLN, VCAN, ZEB1 and ZEB2) were upregulated in patients co-overexpressing TAZ-AXL-CTGF. This TAZ-AXL-CTGF gene expression signature (GES) was then applied to Connectivity Map to identify small molecules that could potentially be utilized to reverse this GES. Of the top 20 small molecules identified by connectivity map, amiloride (a potassium sparing diuretic,) and tretinoin (all-trans retinoic acid) have shown therapeutic promise in inhibition of colon cancer cell growth. Using MyStats, we found that low level expression of either ANO1 or SQLE were associated with a better prognosis in patients who co-overexpressed TAZ-AXL-CTGF, and that ANO1 was an independent predictor of survival together with TAZ-AXL-CTGF. Finally, we confirmed that TAZ regulates Axl, and plays an important role in clonogenicity and non-adherent growth in vitro and tumor formation in vivo. These data suggest that TAZ could be a therapeutic target for the treatment of colon cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

TAZ Expression as a Prognostic Indicator in Colorectal Cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Recent works also studied other potential markers in relation to polyp characteristics: for the serum sulfatase activity, differences regarding the number of adenomas (single or multiple) were significant [23]; serum leptin, adiponectin and resistin also differed between controls and patients with adenomas or CRC, though there was no relationship with dysplasia, histopathology or polyp localization [24]. …”

Section: Discussionmentioning

confidence: 99%

Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas

et al. 2010

View full text Add to dashboard Cite

BackgroundSerum CD26 (sCD26) levels were previously found diminished in colorectal cancer (CRC) patients compared to healthy donors, suggesting its potential utility for early diagnosis. Therefore we aimed to estimate the utility of the sCD26 as a biomarker for CRC and advanced adenomas in a high-risk group of patients. The relationship of this molecule with polyp characteristics was also addressed.MethodssCD26 levels were measured by ELISA in 299 symptomatic and asymptomatic patients who had undergone a colonoscopy. Patients were diagnosed as having no colorectal pathology, non-inflammatory or inflammatory bowel disease, polyps (hyperplastic, non-advanced and advanced adenomas) or CRC.ResultsAt a 460 ng/mL cut-off, the sCD26 has a sensitivity and specificity of 81.8% (95% CI, 64.5-93.0%) and 72.3% (95% CI, 65.0-77.2%) for CRC regarding no or benign colorectal pathology. Clinicopathological analysis of polyps showed a relationship between the sCD26 and the grade of dysplasia and the presence of advanced adenomas. Hence, a 58.0% (95% CI, 46.5-68.9%) sensitivity detecting CRC and advanced adenomas was obtained, with a specificity of 75.5% (95% CI, 68.5-81.0%).ConclusionsOur preliminary results show that measurement of the sCD26 is a non-invasive and reasonably sensitive assay, which could be combined with others such as the faecal occult blood test for the early diagnosis and screening of CRC and advanced adenomas. Additional comparative studies in average-risk populations are necessary.

show abstract

Phosphoryl and Sulfuryl Transfer☆

Brandão¹,

Hengge²

2016

Reference Module in Chemistry, Molecular Sciences and Chemical Engineering

View full text Add to dashboard Cite

Serum sulfatase activity is more elevated in colonic adenomas than cancers

Cited by 6 publications

References 19 publications

TAZ Expression as a Prognostic Indicator in Colorectal Cancer

TAZ Expression as a Prognostic Indicator in Colorectal Cancer

Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas

Phosphoryl and Sulfuryl Transfer☆

Contact Info

Product

Resources

About